INTRODUCTION
============

Health risk of osteoporosis is increasing in Korean women and there were many trials to reduce and prevent osteoporotic fracture risk ([@B1], [@B2]). Vitamin K plays a role in bone metabolism and may decrease the risk of fracture ([@B3], [@B4]). Vitamin K also acts synergistically with Vitamin D on bone mineral density (BMD) and positively influences the balance of calcium, a key mineral in bone metabolism. As a cofactor for carboxylase activity, vitamin K facilitates the gamma-carboxylation of osteocalcin to increase the formation of bone ([@B5]). If the process of gamma-carboxylation is hindered by lack of vitamin K, the concentration of undercarboxylated osteocalcin (UcOC), which has low affinity to hydroxyapatite in bone, increases. An inverse relation between UcOC and BMD, and high serum UcOC levels in women in their 20 sec and 50 sec was recently reported ([@B6]). Since high UcOC level may make women in their 50 sec vulnerable to bone fracture, vitamin K supplementation may be worthwhile for women of this age group to improve BMD.

However, the effects of vitamin K supplementation are controversial. Vitamin K supplementation provided protection against fractures, age related BMD decline, and osteoporosis in some studies ([@B7]-[@B9]), while other studies do not support a BMD benefit of vitamin K supplementation ([@B10]-[@B14]). Although studies examining the effects of vitamin K supplementation on BMD or osteoporosis have been conducted in many Asian countries ([@B15]-[@B18]), the role of vitamin K in bone health in Korean postmenopausal women remains unclear.

The present intervention study was designed to test the effects of vitamin K supplementation with vitamin D and calcium for 6 months on BMD and UcOC among the advanced postmenopausal Korean women over sixty years old.

MATERIALS AND METHODS
=====================

Subjects and study design
-------------------------

We enrolled the advanced postmenopausal women over 60-yr-old, who did not want to take anti-resorptive agent such as bisphosphonate. Therefore, postmenopausal women over sixty years old living in Seoul, Korea, who visited the Out Patients Clinic at Cha Hospital in Seoul from January-May 2010 were recruited (n = 385) ([Fig. 1](#F1){ref-type="fig"}). Of those screened, 103 women were excluded for taking vitamin K, anti-lipid medications, hormone replacement therapy, or medications influencing bone metabolism aspects such as bisphosphonate, calcitonin, steroids, phenytoin, carbamazepine, rifampicin, heparin, and warfarin. As well, 199 women with diabetes, hypertension, body mass index (BMI) \> 30 kg/m^2^, or metabolic bone diseases were excluded. Five other subjects withdrew before randomization for personal reasons. The remaining 78 women were randomly assigned to either the treatment group (vitamin K, n = 40) or a control group (n = 38). For 6 months, the treatment group received 15 mg of vitamin K~2~ (menatetrenone) three times a day after every meal, combination form containing 400 IU of active vitamin D~3~ once a day, and 315 mg of calcium carbonate twice daily. During the same period, the control group received 400 IU of vitamin D and 315 mg of calcium twice daily. During the course of the study, 33 women dropped out due to relocation or loss to follow-up. Forty five women completed the study.

Fasting blood (10 hr of fasting in the morning) was collected at baseline and at months 3 and 6. Total cholesterol, triglyceride and high density lipoprotein (HDL) cholesterol were measured by an enzymatic colorimetric assay using a model 7600 apparatus (Hitachi, Tokyo, Japan). The BMD in the lumbar spine (L1-L4) and femur neck, and ward measurements were performed using a QDR 4500 apparatus (Hologic, Waltham, MA, USA) at baseline and 6 months. The serum UcOC was assayed by an enzyme-linked immunosorbent assay using two monoclonal antibodies. Anti-osteocalcin (OC) antibody and a solid-phase anti-Glu 21, 24-OC antibody with recombinant human UcOC (Takara Shuzo, Shiga, Japan) were used. The coefficients of variation (CVs) in the intra- and inter-assay were 7.3% and 9.7%, respectively. CV was measured twice and the average was determined. The study participants reported their medications to the principal investigators at screening, and at months 3 and 6, and were interviewed about side effects at every visit. For assess study compliance, the remaining pill count was checked at all visits, and blood samples were collected at baseline and months 3 and 6.

Statistical analysis
--------------------

An independent t test was used to compare the baseline demographics and any changes that occurred after 6 months of intervention between the vitamin K group and the control group. To compare any changes in each group after 6 months, the paired t test was used. An intention to treat (ITT) analysis was conducted to obtain standardized outcome variables. In addition, perprotocol (PP) analysis of the 45 subjects was also conducted. A *P* value \< 0.05 was statistically significant. These analyses were done using SPSS version 18.0 (SPSS, Chicago, IL, USA).

Ethics statements
-----------------

All participants provided written informed consent and this study was reviewed and approved by the institutional review board of Cha Hospital (EKI-GLA-06-32).

RESULTS
=======

A total of 385 postmenopausal women over sixty were screened and 78 women were enrolled in the study ([Fig. 1](#F1){ref-type="fig"}). The main reasons for ineligibility were the used of restricted medications and occurrence of diseases that could affect bone metabolism. In the ITT analysis comparing the characteristics of the vitamin K group with the control group ([Table 1](#T1){ref-type="table"}), the age at menopause in the vitamin K group (49.6 ± 2.7 yr) was significantly different from the age at menopause in the control group (50.8 ± 1.7 yr, *P* = 0.03). Other characteristics did not differ in the treatment group in both ITT and PP analyses. In the PP analysis ([Table 2](#T2){ref-type="table"}), characteristics of women in the vitamin K group were not different from those in the control group. The mean (± SD) age, age at menopause, and duration of menopause were 67.3 ± 6.3, 50.6 ± 1.9, and 16.6 ± 6.8 yr, respectively, in the vitamin K group and 67.8 ± 6.4, 51.0 ± 1.9, and 16.8 ± 7.0 yr, respectively, in the control group. BMDs in lumbar and femur were similar in both the vitamin K and the control groups. In addition, the UcOC concentration in the vitamin K group (2.1 ± 1.7 ng/dL) was not significantly different from that in the control group (1.5 ± 1.0 ng/dL, *P* = 0.214). The mean (± SD) osteocalcin level was 9.6 ± 6.4 ng/dL in the vitamin K group and 11.7 ± 6.4 ng/dL in the control group. There were no significant differences in blood urea nitrogen, creatinine, calcium and serum bone-specific alkaline phosphatase (BSALP) between the vitamin K and the control groups. The BMD in L1-L4 and femur neck, and in the ward in the vitamin K group were not different from those in the control group. The serum UcOC level in the vitamin K group (2.1 ± 1.7 ng/dL) was higher than that in the control group (1.5 ± 1.0 ng/dL), but showed no significant difference (*P* = 0.21). Osteocalcin level was nonsignificantly lower in the vitamin K group (9.6 ± 6.4 ng/dL) than in the control group (11.7 ± 6.4 ng/dL, *P* = 0.29). The BSALP level was 189.5 ± 64.5 µg/L in the vitamin K group and 185.6 ± 46.0 µg/L in the control group (*P* = 0.827). No significant differences in BMD and biomarker values between the vitamin K and the control groups indicated that the randomization worked well. The ITT analysis showed similar results.

After 6 months of treatment, the L3 BMD in the vitamin K group compared to the control group increased statistically significantly (0.01 ± 0.03 g/cm^2^ vs -0.008 ± 0.04 g/cm^2^, *P* = 0.049). Compared to BMD at baseline, BMD in femur at month 6 was significantly increased in both the vitamin K and the control groups. However, after 6 months of treatment, BMD in the vitamin K group was not statistically different from BMD in the control group. In addition, compared to the baseline, the vitamin K group significantly decreased UcOC concentration (-1.6 ± 1.6 ng/dL, *P* \< 0.01), whereas the UcOC level in the control group did not change (-0.4 ± 1.1 ng/dL). The change in UcOC concentration in the vitamin K group, but not in the control group, confirmed the compliance of the participants in the vitamin K group with the study protocol. Osteocalcin was also non-significantly increased in the vitamin K group (1.6 ± 5.8 ng/dL), but not in the control group (-1.1 ± 6.0 ng/dL). Triglyceride level decreased in the vitamin K group (-10.0 ± 59.1 ng/dL) ([Table 3](#T3){ref-type="table"}). Three people complained of nausea sensation twice after taking vitamin K. No other participants including people in the control group reported adverse events during the study period.

In summary, after 6 months treatment of vitamin K to the postmenopausal women over sixty, the L3 BMD increased significantly compared to the control group. In addition, the changes in some biochemical markers differed by treatment. Compared to the control group, the vitamin K group significantly decreased serum UcOC concentration (*P* = 0.008). Osteocalcin level was higher in the vitamin K group than in the control group, but the difference was not significant (*P* = 0.14).

DISCUSSION
==========

In this study, supplementation with vitamins K and D, and with calcium for 6 months of treatment significantly improved the L3 BMD compared to supplementation with vitamin D and calcium in postmenopausal Korean women over sixty years old. In addition, femur BMD was increased in the vitamin K group (vitamin K + vitamin D + calcium), but a similar increase was observed in the control group (vitamin D + calcium supplementation). The UcOC concentration significantly decreased in the vitamin K group compared to the control group (*P* \< 0.01), and the osteocalcin level increased nonsignificantly in the vitamin K group (*P* = 0.14). The triglyceride level decreased in the vitamin K group, but was not statistically different from the control group. Similar results were observed in the ITT analysis.

When vitamin K concentration in the body is low, insufficient amount of osteocalcin completes γ-carboxylation; consequently, UcOC concentration increases and the affinity to calcium to bone matrix decreases. Gla-residues of osteocalcin combine with calcium and require vitamin K to activate the reaction site. Therefore, measuring UcOC concentration is a more accurate method of monitoring vitamin K than prothrombin in the liver ([@B19]).

In a previous cross-sectional study in postmenopausal women, elevated serum UcOC and low spinal BMD were observed in the low plasma phylloquinone (vitamin K~1~) group ([@B20]). In another study, healthy elderly Scottish women who took vitamin K~1~ with vitamin D and calcium showed a sustained increase in BMD at the site of the ultradistal radius in comparison with women taking calcium and vitamin D ([@B21]). A combined vitamin K~2~ therapy with vitamin D~3~ for postmenopausal Japanese women produced low serum UcOC and improved BMD values ([@B22]). In an examination of the effects of vitamin K~2~ (45 mg/day) supplementation with calcium (1,500 mg/day) on lumbar BMD in postmenopausal women in Indonesia, a meaningful increase in BMD and a decrease in UcOC level were reported ([@B18]). On the other hand, a study reported no vitamin K effect on BMD in North American women, prompting the suggestion that women receiving calcium and vitamin D supplements do not need additional vitamin K supplementation to prevent osteoporosis ([@B23]). Another recent study of vitamin K~1~ supplementation for 2-4 yr in Canadian women also reported no benefits on age-related decline in BMD ([@B12]). Our study showed that compared to the control group that took vitamin D and calcium, additional vitamin K supplementation to vitamin D and calcium improved L3 BMD in Korean postmenopausal women over sixty. Our previous cross-sectional study involving Korean women reported an inverse association between UcOC and BMD ([@B6]). This dichotomy may partially be due to an ethnic difference and subjects\' age in the bone metabolism or response to vitamin K or UcOC. A study of inflammatory bowel disease patients in Japanese women reported a decrease in the concentrations of vitamin K and D, and a resulting decrease in BMD ([@B24]). The foregoing results imply that ethnic-related diversity in gastrointestinal absorption may explain the different response to vitamin K supplement and its subsequent effects on BMD ([@B25]).

Several studies reported that obesity has been related to the level of vitamin K in adipose tissue, reflecting it\'s fat-soluble nature. In one study, obese patients displayed a lower UcOC concentration and their UcOC/osteocalcin ratio was negatively related with body mass index ([@B26]). Another study reported that people with a high serum triglyceride level had high BMD in skeletal muscles ([@B27]). On the other hand, adult obesity has been inversely related to circulating indicators of serum vitamin K ([@B28]).

Limitations of the study were the small number of participants, relatively high dropout rate, and lack of a placebo group (i.e., no supplementation). The dosages of vitamin K, vitamin D and calcium and the duration of treatment may have been insufficient to induce responses in related biochemical markers and total BMD. Moreover, we did not measure and compare the dietary vitamin K intake. Also, bone quality was not measured, which might be only a minor limitation. A previous study ([@B6]) suggested that UcOC concentration is inversely associated with age, with higher UcOC concentrations in younger women. This suggests that the effect of the vitamin K on osteocalcin may also be age-related. Given the advanced age of our study subjects (mean age 68 yr) and relatively short treatment period, the study may have not been able to discern an increase all part of BMD. However, it is noteworthy that changes in UcOC concentration among older women have been reported, with UcOC concentration in women in their 50 sec being higher than that in women in their 60 sec and 70 sec ([@B6]). Therefore, vitamin K may be more effective in preventing bone loss or improving BMD in women aged 50-59 yr, especially in perimenopausal women or women with few years of menopause. A study testing the influence of vitamin K supplementation to perimenopausal women or women with few years of menopause for more than 6 months is needed. In addition, inconsistent findings from different countries suggest that a comparison of Korean data with data from other countries is warranted. A study design involving a longer duration of vitamin K supplementation and with postmenopausal women having a short duration of menopause may prove valuable. Finally, physical activity was not measured.

In conclusion, in this randomized study, supplementation with vitamin K, D and calcium for 6 months improves L3 BMD and reduces UcOC concentration in Korean postmenopausal women over sixty.
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This study is to evaluate effects of vitamin K supplementation on bone mineral density (VMD) in postmenopausal Korean women. 78 postmenopausal women over sixty years old were assigned to either control (Calcium & Vitamin D, n = 40) or vitamin K-supplemented group (Calcium, Vitamin D & Vitamin K, n = 38). After 6 months of treatment, the vitamin K group showed decrease of undercarboxylated osteocalcin and increase of BMD. The Intention to Treat (ITT) analysis showed the same result. Such result is contrary to the previous study in North American postmenopausal women.
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Characteristics of study participants at baseline by treatment group: ITT analysis

![](jkms-26-1093-i001)

All values are mean ± standard deviation. *P* values are from independent t test. D, vitamin D; Ca, calcium supplement; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; HDL, high-density lipoprotein; BMD, bone mineral density; UcOC, undercarboxylated osteocalcin; BSALP, serum bone-specific alkaline phosphatase.
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Characteristics of study participants at baseline by treatment group: PP analysis
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All values are mean ± standard deviation. *P* values were from independent t test. D, vitamin D; Ca, calcium supplement; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; HDL, high-density lipoprotein; BMD, bone mineral density; UcOC, undercarboxylated osteocalcin; BSALP, serum bone-specific alkaline phosphatase.
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Changes in BMD and biochemical markers from the baseline to 6 months
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All values are mean ± standard deviation. *P* values from independent t test. D, vitamin D; Ca, calcium supplement; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMD, bone mineral density; UcOC, undercarboxylated osteocalcin; BSALP, serum bone-specific alkaline phosphatase; BUN, blood urea nitrogen; HDL, high-density lipoprotein.
